CBD Global Sciences Past Earnings Performance
Past criteria checks 0/6
CBD Global Sciences's earnings have been declining at an average annual rate of -4.3%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been declining at an average rate of 40.5% per year.
Key information
-4.3%
Earnings growth rate
20.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -40.5% |
| Return on equity | n/a |
| Net Margin | -1,253.7% |
| Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How CBD Global Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 0 | -5 | 2 | 0 |
| 31 Dec 21 | 0 | -5 | 3 | 0 |
| 30 Sep 21 | 0 | -4 | 2 | 0 |
| 30 Jun 21 | 0 | -9 | 3 | 0 |
| 31 Mar 21 | 0 | -6 | 3 | 0 |
| 31 Dec 20 | 0 | -5 | 2 | 0 |
| 30 Sep 20 | -2 | -14 | 4 | 0 |
| 30 Jun 20 | 0 | -15 | 4 | 0 |
| 31 Mar 20 | 1 | -8 | 4 | 0 |
| 31 Dec 19 | 2 | -9 | 4 | 0 |
| 31 Jul 19 | 0 | 0 | 0 | 0 |
| 31 Dec 18 | 1 | -3 | 3 | 0 |
Quality Earnings: CBDN is currently unprofitable.
Growing Profit Margin: CBDN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CBDN is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare CBDN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBDN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: CBDN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.